Association of Prostate-Specific Antigen Density and Gleason score of Positive Surgical Margin with Biochemical Recurrence in Prostate Cancer
Men's Health Journal,
Vol. 6 No. 1 (2022),
1 January 2022
,
Page e5
https://doi.org/10.22037/mhj.v6i1.36846
Abstract
Background: We aimed to investigate the association between prostate specific antigen (PSA) density and Gleason score of the positive surgical (PSM) margin after radical prostatectomy with biochemical recurrence in patients with prostate cancer. Materials and Methods: In this retrospective cohort study, patients with prostate cancer referred to Hasheminejad Hospital in Tehran, Iran, during 2009-2019, who underwent radical prostatectomy were enrolled through the convenience sampling method. The follow-up period was determined as at least one year after radical prostatectomy to determine biochemical recurrence. Prostate-specific antigen density (PSAD) and the Gleason score of surgical specimen and positive surgical margins (PSM) were evaluated and their association with biochemical recurrences was investigated. Results: One hundred and three patients were assessed. The overall biochemical recurrence rate was 48.5% with a mean follow-up of 24 months (12-42 months) and an average time to biochemical recurrence of 18 months (16-20 months). BCR-free (Biochemical recurrence-free) survival rates of patients divided based on the PSAD cut-off point (0.205 ng/ml/cc) were significantly different using the log-rank test (P= 0.008) (85.7%, 57.1%, and 14.3% for values ≤ 0.205 ng/ml/c versus 55.8%, 20.9%, and 0% for values ˃ 0.205 ng/ml/cc, respectively for 1-, 2- and 3-year survival). Moreover, Cox regression showed that the Gleason score of PSM, the Gleason score of the surgical specimen, and the PSAD predicted biochemical recurrence more, respectively. Conclusion: PSAD and PSM Gleason scores were strong predictors of biochemical recurrence after radical prostatectomy and their use along with other common indicators including tumor grade and stage and PSA level can increase the accuracy of risk assessment in patients with prostate cancer.
- Prostate cancer
- Biochemical recurrence
- Positive surgical margin
- Radical prostatectomy
- PSA density
- Gleason score
How to Cite
References
Masip C. Prostate cancer epidemiology. Archivos espanoles de urologia. 2014;67(5):373-82.
Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, et al. Prostate cancer. Journal of the National Comprehensive Cancer Network. 2010;8(2):162-200.
Brawley OW. Prostate cancer epidemiology in the United States. World journal of urology. 2012;30(2):195-200.
Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harbor perspectives in medicine. 2018;8(12):a030361.
Rawla P. Epidemiology of prostate cancer. World journal of oncology. 2019;10(2):63.
Tenke P, Horti J, Balint P, Kovacs B. Prostate cancer screening. Recent Results Cancer Res. 2007;175:65-81.
Kawachi MH, Bahnson RR, Barry M, Busby JE, Carroll PR, Carter HB, et al. Prostate cancer early detection. Journal of the National Comprehensive Cancer Network. 2010;8(2):240-62.
Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, et al. Early detection of prostate cancer: AUA Guideline. The Journal of urology. 2013;190(2):419-26.
Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer–specific mortality following biochemical recurrence after radical prostatectomy. Jama. 2005;294(4):433-9.
Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. The Journal of urology. 2003;169(2):517-23.
Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco Jr FJ, Lilja H, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol. 2006;24(24):3973-8.
Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, et al. Prostate cancer–specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. Jama. 2008;299(23):2760-9.
Khan MA, Partin AW, Mangold LA, Epstein JI, Walsh PC. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. Urology. 2003;62(5):866-71.
Trock BJ, Guo CC, Gonzalgo ML, Magheli A, Loeb S, Epstein JI. Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system. The Journal of urology. 2009;182(4):1364-70.
Hsu M, Chang SL, Ferrari M, Nolley R, Presti JC, Jr., Brooks JD. Length of site-specific positive surgical margins as a risk factor for biochemical recurrence following radical prostatectomy. Int J Urol. 2011;18(4):272-9.
Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367:203-13.
Sharkey J, Cantor A, Solc Z, Huff W, Chovnick SD, Behar RJ, et al. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice. Brachytherapy. 2005;4(1):34-44.
Zargar MA SP, Kabir A, Dehghanee-e-Firoozabadi MH. Evaluation of the relationship between serum free testosterone and gleason score of the prostatic biopsy in patient with prostate cancer. Iranian journal of urology. 2002;9(36):1-7.
Gallina A, Chun FK-H, Briganti A, Shariat SF, Montorsi F, Salonia A, et al. Development and split-sample validation of a nomogram predicting the probability of seminal vesicle invasion at radical prostatectomy. European urology. 2007;52(1):98-105.
Datta K, Muders M, Zhang H, Tindall DJ. Mechanism of lymph node metastasis in prostate cancer. Future oncology. 2010;6(5):823-36.
Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA: a cancer journal for clinicians. 2002;52(3):154-79.
Roach M, Moughan J, Lawton CA, Dicker AP, Zeitzer KL, Gore EM, et al. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. The Lancet Oncology. 2018;19(11):1504-15.
Freedland SJ, Kane CJ, Presti JC, Jr., Terris MK, Amling CL, Dorey F, et al. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base. J Urol. 2003;169(3):969-73.
Pollack A, Lankford S, Zagars GK, Babaian RJ. Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy. Cancer. 1996;77(8):1515-23.
Song C, Kang T, Yoo S, Jeong IG, Ro JY, Hong JH, et al. Tumor volume, surgical margin, and the risk of biochemical recurrence in men with organ-confined prostate cancer. Urol Oncol. 2013;31(2):168-74.
Freedland SJ, Partin AW, Epstein JI, Walsh PC. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b. Cancer. 2004;100(8):1646-9.
Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ, Jr., Dotan ZA, Fearn PA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006;98(10):715-7.
Liesenfeld L, Kron M, Gschwend JE, Herkommer K. Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy. J Urol. 2017;197(1):143-8.
Nowroozi MR, Momeni SA, Ohadian Moghadam S, Ayati E, Mortazavi A, Arfae S, et al. Prostate-Specific Antigen Density and Gleason Score Predict Adverse Pathologic Features in Patients with Clinically Localized Prostate Cancer. Nephrourol Mon. 2016;8(6):e39984.
Radwan MH, Yan Y, Luly JR, Figenshau RS, Brandes SB, Bhayani SB, et al. Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure. Urology. 2007;69(6):1121-7.
Jones TD, Koch MO, Bunde PJ, Cheng L. Is prostate-specific antigen (PSA) density better than the preoperative PSA level in predicting early biochemical recurrence of prostate cancer after radical prostatectomy? BJU Int. 2006;97(3):480-4.
Kang HW, Jung HD, Lee JY, Kwon JK, Jeh SU, Cho KS, et al. Prostate-specific antigen density predicts favorable pathology and biochemical recurrence in patients with intermediate-risk prostate cancer. Asian J Androl. 2016;18(3):480-4.
Koie T, Mitsuzuka K, Yoneyama T, Narita S, Kawamura S, Kaiho Y, et al. Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy. Int J Clin Oncol. 2015;20(1):176-81.
Sfoungaristos S, Perimenis P. Evaluating PSA density as a predictor of biochemical failure after radical prostatectomy: results of a prospective study after a median follow-up of 36 months. International Scholarly Research Notices. 2013;2013.
Evren I, Hacıislamoğlu A, Ekşi M, Yavuzsan AH, Baytekin F, Çolakoğlu Y, et al. The impact of single positive surgical margin features on biochemical recurrence after robotic radical prostatectomy. International braz j urol. 2019;45(1):45-53.
Kates M, Sopko NA, Han M, Partin AW, Epstein JI. Importance of reporting the Gleason score at the positive surgical margin site: analysis of 4,082 consecutive radical prostatectomy cases. The Journal of urology. 2016;195(2):337-42.
ÖZKANLI SŞ, Zemheri IE, Yildirim A, Gür HD, Balbay MD, Şenol S, et al. Gleason score at the margin can predict biochemical recurrence after radical prostatectomy, in addition to preoperative PSA and surgical margin status. Turkish journal of medical sciences. 2014;44(3):397-403.
- Abstract Viewed: 175 times
- pdf Downloaded: 127 times